Clinical Trial Update: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update exploring belinostat pharmacokinetics and toxicity guided by UGT1A1 genotype in neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• BELEODAQ (BELINOSTAT)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Carcinoma, Neuroendocrine, Tumor, Neuroendocrine | Phase 2 | Status: RECRUITING